SCHEMBL1103327

SCHEMBL1103327

c1ccc(-c2cc(-c3c4ccccc4c(-c4cc(-c5ccccc5)nc(-c5ccccc5)c4)c4c3cnc3ccccc34)cc(-c3ccccc3)n2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 1/20 0.44
SMN1; SMN2 Q16637 4/20 0.41
LMNA P02545 3/20 0.41
KDM4E B2RXH2 3/20 0.41
PDE10A Q9Y233 1/20 0.41
HPGD P15428 1/20 0.41
ESR1 P03372 2/20 0.40
ESR2 Q92731 2/20 0.40
DHODH Q02127 1/20 0.39
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
MAPT P10636 1/20 0.39
RECQL P46063 1/20 0.39
PDGFRB P09619 1/20 0.39
KDR P35968 1/20 0.39
FLT3 P36888 1/20 0.39
GPR3 P46089 1/20 0.39
TOP1 P11387 1/20 0.38
ACACA Q13085 1/20 0.38
PDPK1 O15530 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1103556 0.88 SMN1; SMN2 (0.39) ACHESMN1; SMN2LMNAKDM4EPDE10A
SCHEMBL1103333 0.88 CYP19A1 (0.52) SMN1; SMN2LMNAKDM4EHPGDDHODH
SCHEMBL1103282 0.86 ESR1 (0.39) SMN1; SMN2LMNAKDM4EHPGDESR1
SCHEMBL1105452 0.86 ESR1 (0.43) SMN1; SMN2LMNAKDM4EHPGDESR1
SCHEMBL1103377 0.85 ESR1 (0.41) SMN1; SMN2LMNAKDM4EHPGDESR1
SCHEMBL1103486 0.84 ESR1 (0.42) SMN1; SMN2LMNAKDM4EHPGDESR1
SCHEMBL1103491 0.84 ESR1 (0.42) SMN1; SMN2LMNAKDM4EHPGDESR1
SCHEMBL1103479 0.84 ESR1 (0.42) SMN1; SMN2LMNAKDM4EHPGDESR1
SCHEMBL1103449 0.84 ESR1 (0.42) SMN1; SMN2LMNAKDM4EHPGDESR1
SCHEMBL1103337 0.84 MEN1 (0.44) ACHESMN1; SMN2LMNAKDM4EPDE10A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 US disclosed
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same ORMDL3, OCIAD2, OCIAD1 ACHE 1080/4885SMN1; SMN2 4091/4885LMNA 2738/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.